Fundraising Fox
/Companies
Sign in

Kinoxis Therapeutics

Melbourne, AU · Founded 2017 · 18 employees on LinkedIn · 2 known investors

Find your way into Kinoxis Therapeutics

Sign up to see every warm intro you have to Kinoxis Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Kinoxis Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Kinoxis Therapeutics develops novel therapeutics targeting inflammatory signaling pathways in the nervous system to address unmet needs in CNS disorders, with initial focus on treatments for agitation and pain.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Kinoxis Therapeutics was founded in 2017 by Hugh Alsop and Michael Bowen.

HAHugh Alsop
Hugh AlsopChief Executive Officer, Co-FounderHugh Alsop is Chief Executive Officer and co-founder of Kinoxis Therapeutics, a clinical-stage Australian biotech company developing small-molecule therapeutics for central nervous system disorders. He holds a Bachelor of Science in Chemistry from the University of Melbourne and an MBA from Melbourne Business School, and brings over 25 years of pharmaceutical and biotechnology executive experience across drug development, commercialisation, and business development roles at companies including Mayne Pharma, Acrux Limited, and Phosphagenics.
MBMichael Bowen
Michael BowenChief Scientific Officer, Co-Founder

Investors · 2

UniSeed Pty Ltd.listed by UniSeed Pty Ltd.Brisbane · $165K – $330K

How we know: UniSeed Pty Ltd.'s portfolio page · the VCSheet dataset · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Kinoxis Announces Plan to Evaluate KNX100 for the Treatment of Alcohol Use Disorder - Kinoxis Therapeuticskinoxistherapeutics.com · May 2024Kinoxis Completes $5M Financing Round and Advances Lead Program Through Key Toxicology Studies - Kinoxis Therapeuticskinoxistherapeutics.com · Dec 2020

Frequently asked questions

What does Kinoxis Therapeutics do?
Kinoxis Therapeutics develops novel therapeutics targeting inflammatory signaling pathways in the nervous system to address unmet needs in CNS disorders, with initial focus on treatments for agitation and pain.
Who founded Kinoxis Therapeutics?
Kinoxis Therapeutics was founded by Hugh Alsop, Michael Bowen in 2017.
Who are Kinoxis Therapeutics's investors?
Kinoxis Therapeutics's investors include Stoic VC, UniSeed Pty Ltd..
Where is Kinoxis Therapeutics headquartered?
Kinoxis Therapeutics is headquartered in Melbourne, AU.